NewLimit Raises $435M to advance longevity medicine trials, expand ageing research programmes and accelerate clinical growth.

NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...

Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today ...